The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex

Sulbactam-durlobactam is a β-lactam/β-lactamase inhibitor combination currently in development for the treatment of infections caused by Acinetobacter, including multidrug-resistant (MDR) isolates. Although sulbactam is a β-lactamase inhibitor of a subset of Ambler class A enzymes, it also demonstra...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Donnell, John P, Bhavnani, Sujata M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
SUL-DUR Supplement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150273/
https://www.ncbi.nlm.nih.gov/pubmed/37125469
http://dx.doi.org/10.1093/cid/ciad096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150273/
https://www.ncbi.nlm.nih.gov/pubmed/37125469
http://dx.doi.org/10.1093/cid/ciad096

Ejemplares similares